Clinical Pearls for Oncologists Treating Patients With BCG-Unresponsive NMIBC
December 21st 2023BCG-unresponsive NMIBC requires vigilant surveillance during new treatments to avoid missing signs of progression and avoid delaying cystectomy, which remains the best chance for cure if intravesical therapies are failing.
Watch
Woyach Discusses Updated BRUIN Data of Pirtobrutinib in CLL/SLL
December 20th 2023Jennifer A. Woyach, MD, discusses background and updated findings from the phase 1/2 BRUIN study of pirtobrutinib for the treatment of heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma after prior treatment with a covalent Bruton tyrosine kinase inhibitor.
Watch
IsKia: Isa-KRd vs KRd as Pre-Transplant Induction and Post-Transplant Consolidation in NDMM
December 19th 2023Experts on multiple myeloma review recent data updates from the IsKia study looking at Isa-KRd vs KRd as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma.
Watch
PERSEUS: Dara-VRd vs VRd in Patients with NDMM Eligible for Autologous Stem Cell Transplantation
December 19th 2023Following ASH 2023, Jens Hillengass, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent data from the PERSEUS study investigating Dara-VRd in newly diagnosed multiple myeloma.
Watch
Novel Combination Therapy Impresses With Safety/Efficacy in DLBCL
December 19th 2023Christopher J. Melani, MD, discusses updated data from the phase 1b/2 ViPOR trial of the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, in patients with diffuse large B-cell lymphoma.
Watch
Second-Line Treatment and Future of Treating Advanced RAI-Refractory DTC
December 19th 2023Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.
Watch